Disease:
Osteosarcoma

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(build 137)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs13181 ERCC2 Lys751Gln, ERCC2:2251A>C, ERCC2:Lys751Gln, c.2251A>C, g.18123137T>G, g.23927A>C, g.45854919T>G, p.Lys751Gln, rs13181:T>G
T > G
Missense
Lys751Gln
No VIP available No Clinical Annotations available VA
rs1799735 3-bp deletion, GSTM3, c.468+24delG, c.468+24delGinsAGG, g.110280254delC, g.110280254delCinsCCT, intron 6, n.702+24delG, n.702+24delGinsAGG, rs1799735:AGG/-
C > CCT
C > -
Intronic
No VIP available No Clinical Annotations available VA
rs1799793 XPD Asp312Asn, XPD:Asp312Asn, c.862G>A, c.934G>A, g.11587G>A, g.18135477C>T, g.45867259C>T, p.Asp288Asn, p.Asp312Asn
C > T
Missense
Asp288Asn
No VIP available No Clinical Annotations available VA
rs1801133 677C>T, A222V, Ala222Val, C677T, MTHFR: c.677C>T, MTHFR:667C>T, c.665C>T, g.11778965G>A, g.11856378G>A, g.14783C>T, g.7861110G>A, p.A222V, p.Ala222Val
G > A
Missense
Ala222Val
No VIP available No Clinical Annotations available VA
rs1805087 MS 2756A>G, MS D919G, MTR:2756A>G, MTR:Asp919Gly, c.2756A>G, g.237048500A>G, g.30566279A>G, g.94920A>G, p.Asp919Gly
A > G
Missense
Asp919Gly
No VIP available No Clinical Annotations available VA
rs2228001 XPC Lys939Gln, XPC:Lys939Gln, c.2704C>A, c.2795C>A, c.2815C>A, g.14127449G>T, g.14187449G>T, g.37724C>A, n.2795C>A, p.Gln902Lys, p.Gln939Lys, rs2228001:A>C
G > T
Missense
Gln902Lys
No VIP available No Clinical Annotations available VA
rs34743033 28-bp tandem repeats, CCGCGCCACTTGGCCTGCCTCCGTCCCG, TSER*2, TSER*3, TYMS: 28 bp tandem repeat, TYMS: 2R, TYMS: TSER *2/*3, TYMS:TSER 28-basepair 5'UTR enhancer region repeat
(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3/4
Not Available
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 137

Overview

Alternate Names: 
Synonym
Osteoblastic osteosarcoma; Osteoblastic sarcoma; Osteochondrosarcoma; Osteogenic Sarcoma; Osteogenic Sarcomas; Osteogenic sarcoma; Osteogenic sarcoma, NOS; Osteosarcoma, no ICD-O subtype; Osteosarcomas; Sarcoma, Osteogenic; Sarcomas, Osteogenic
PharmGKB Accession Id: PA445601
External Vocabularies
  • MeSH: D012516 - Osteosarcoma
  • SnoMed Clinical Terminology: 21708004 - Osteosarcoma
  • Unified Medical Language System: C0029463 - C0029463
  • MedDRA: 10031244 - Osteogenic sarcoma
  • NDF-RT: N0000002678 - Osteosarcoma [Disease/Finding]

Curated Information ?

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
No related diseases are available

Publications related to Osteosarcoma: 17

No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics. 2012. Khrunin Andrey, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Caffeine activates tumor suppressor PTEN in sarcoma cells. International journal of oncology. 2011. Miwa Shinji, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics. 2011. Giovannetti Elisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics. 2011. Lamas Maria J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. The pharmacogenomics journal. 2011. Biason P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. British journal of clinical pharmacology. 2010. Etienne-Grimaldi Marie-Christine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenetics and genomics. 2010. Salinas-Souza Carolina, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics. 2010. Sakano Shigeru, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. The pharmacogenomics journal. 2010. Khrunin A V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
[Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study]. Medycyna wieku rozwojowego. 2009. ¿ugowska Iwona, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenetics and genomics. 2009. Bradbury Penelope A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. The Journal of pediatrics. 2009. Patiño-García Ana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. The pharmacogenomics journal. 2009. Caronia D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines. Pediatric blood & cancer. 2008. Bodmer N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. The pharmacogenomics journal. 2008. Riedemann L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007. Mensah-Osman Edith J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. British journal of cancer. 2004. Stoehlmacher J, et al. PubMed